Feed TRGNF
TR
Transgene S.A. TRGNF OTC · Healthcare · France
$0.75 +0.00% +$0.00
Summary
66 / 100 · Bulios Score
Valuation 100Growth -Profitability 80Quality 0Debt 69Stability 100
What speaks for it
- Out of every 100 EUR of revenue, 809 EUR is left as net profit.
- It holds more cash than debt: 4.24M € against 2.18M €.
What to watch
- Revenue fell by 38% a year over the last 3 years.
- It passes only 3 of the 9 points of the Piotroski financial health test.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapIs it growing?
Revenue (EUR)
202520262027
- Analyst estimate
Revenue fell by 14% a year over 5 years. Over the last 3 years it fell by 38% a year.
Growth in detailDoes it make money?
Very wellOver the last 12 months it made a loss of 33.8M €.
Profitability in detailIs it financially healthy?
YesCash and short-term investments 92.7M €
Debt 2.18M €
Free cash flow over 12 months -39.1M €
Over the last 12 months it spent more cash than it brought in. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.